Zhongke Venture Capital

The firm operates within the technology transfer ecosystem of the Chinese Academy of Sciences, which oversees more than 100 research institutes across China. Zhongke Venture Capital focuses specifically on commercializing intellectual property developed at CAS-affiliated laboratories, functioning as a venture formation vehicle for research outcomes that have commercial application. This relationship provides the firm with proprietary access to deal flow originating inside China's largest state research apparatus.

Zhongke Venture Capital concentrates on seed and pre-Series A rounds, often serving as the first institutional investor in CAS-originated spinouts. The firm's model emphasizes company formation and technical advisory during the earliest stages of commercialization, typically maintaining involvement through Series A. Later-stage follow-on capital is generally sourced from external venture partners introduced after the initial institutionalization of the company.

The firm's mandate is domestic, centered on the Chongqing-Chengdu economic corridor in southwestern China. Secondary deal flow originates from CAS-linked programs in Beijing and Shanghai. There is no public record of cross-border direct investments or international fund structures. The regulatory framework governing state-owned intellectual property effectively limits the firm to domestic commercialization partnerships.

Deal flow derives primarily from the Chinese Academy of Sciences internal technology transfer pipeline, which routes laboratory-validated intellectual property to affiliated commercialization entities. Zhongke Venture Capital benefits from a structural first-look position on CAS-originated research with commercial potential, giving it access to ventures that are not broadly marketed to external limited partners or independent venture funds. This sourcing model is anchored in institutional relationships rather than a market-facing origination strategy.

No. The firm does not publicly disclose assets under management, fund sizes, or aggregate deployment figures. As a China-domiciled entity operating within the state research ecosystem, its capital formation and fund-level financials are not subject to the same public reporting conventions that apply to Western venture capital firms. The firm's AUM remains undisclosed.